

Technical Report No. 46
Last Mile: Guidance
for Good Distribution
Practices for
Pharmaceutical Products
to the End User



2009

Last Mile: Guidance For Good Distribution Practices For Pharmaceutical Products To The End User Task Force

Task Team Leader : Bella R. Cohen, PharmD, Abbott

Christopher J. Anderson, Cardinal Health

Rafik H. Bishara, PhD, Chair, Pharmaceutical Cold Chain Interest Group (PCCIG), PDA

Chris Chandler, PharmD, US Department of Veterans Affairs, Great Lakes CMOP, QA

James L. Cox, PhD, TempTRIP, LLC

Jean-Pierre Emond, PhD, University of Florida–Polytechnic

Karl I. Kussow, FedEx Custom Critical

Thaddeus Prusik, PhD, Temptime Corporation

Omar Riyal, Abbott

Anthony (TJ) Rizzo, Cold Chain Technologies

Edward J. Smith, PhD, Packaging Science Resources

James Soucey, RPh, Wal-Mart Specialty Pharmacy

David Ulrich, Abbott

Jean Vezina, Blubox LLC

Ronald J. Ziance, PhD, University of Southern Nevada, College of Pharmacy

Last Mile: Guidance for Good Distribution Practices for Pharmaceutical Products to the End User

Technical Report No. 46

ISBN: 978-0-939459-26-1

© 2009 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	6	4.0 EDUCATION TO PROVIDE END USER/RECIPIENT	21
1.1 Purpose	6	4.1 Last Mile Education.....	21
1.2 Scope.....	7	4.2 Good Cold Chain Practice Information for Health Care Professionals (Dispensers).....	21
2.0 GLOSSARY OF TERMS	8	5.0 CONCLUSION	23
3.0 DISTRIBUTION OF TEMPERATURE SENSITIVE PHARMACEUTICAL PRODUCTS	10	6.0 APPENDICES	24
3.1 Transportation Conditions for Last Mile Logistics	10	6.1 Patient Education.....	24
3.1.1 Aircraft	10	6.2 Environmental Considerations	24
3.1.1.1 Transportation Security Administration Cargo Screening Requirement.....	10	6.2.1 Environmental Impact of Packaging Components	24
3.1.2 Truck	11	6.2.1.1 Insulation Materials.....	25
3.1.2.1 Shipping Containers	11	6.2.1.2 Refrigerants	26
3.1.3 Sea	12	6.3 The Waste Stream for Packaging Components and Drug Product.....	27
3.1.4 Implications of Weather	12	6.3.1 Recycling and Regulations.....	27
3.2 Wholesaler Distribution for Refrigerated Pharmaceutical Shipments.....	13	6.3.2 Reverse Logistics	28
3.3 Pedigree and Unit Serialization	15	6.4 Additional On-line Information Services.....	28
3.4 Stability Data.....	16	6.5 Compendia Storage Conditions	30
3.5 Distribution from Point of Dispensing to End Use in Mail Service Pharmacy.....	18	7.0 REFERENCES	32
3.5.1 Maintaining Quality Storage and Shipping in Mail Outpatient Pharmacy.....	18		
3.5.2 Pharmaceutical Packaging for Mail Service Pharmacy Home Delivery.....	19		
3.5.3 Shipping for Home Delivery	19		
3.6 Disaster Plan	20		

1.0 Introduction

Medicinal products and devices requiring controlled temperature storage are subject to highly variable distribution environments. The manufacturer distributes in a well-controlled shipping lane that is routinely monitored for temperature excursions and is subject to uniform, stringent Good Distribution Practices (GDP). Conversely, shipping/distribution regulations vary widely from location to location, and uniform guidelines are lacking. This divergence has proved challenging for the pharmaceutical industry.

Good Distribution Practices are a natural extension of Good Manufacturing Practices, Good Clinical Practices and Good Laboratory Practices, among other requirements for manufacturers of medicinal products and devices. Regulations and guidance for each different custodian in the supply chain can vary by country, state and province. For example:

- The United States Pharmacopeia (USP) Chapter <1079> Good Storage and Shipping Practices offers guidance and procedures on maintaining pharmaceutical integrity throughout the supply chain to the patient.
- The World Health Organization (WHO) provides *Good Distribution Practices for Pharmaceutical Products* (WHO Technical Report Series, No. 937, 2006, Annex 5).
- The European Union issued *Guidelines on Good Distribution Practice of Medicinal Products for Human Use* (94.C 83/03) and Council Directive on the *Wholesale Distribution of Medicinal Products for Human Use* (EEC 9225).
- Canada developed *Guidelines for Temperature Control of Drug Products during Storage and Transportation* (Guide 0069). Additional guidance has been prepared in Ireland, Singapore, Brazil and Austria.
- *PDA Technical Report No. 39, Guidance for Temperature-Controlled Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment* (TR-39) provides global and industry perspectives with further documentation of quality systems.
- Argentina passed Law # 26492, *Regulación de la cadena de frío de los medicamentos*, requiring all pharmaceutical products for human or veterinary use containing temperature-sensitive active ingredients to have a temperature indicator attached by the manufacturer to verify that the cold chain for the product has not broken when it is received by the consumer.

“Last mile” is an often-used logistical term, and in the shipping of pharmaceutical products, is considered to start from the manufacturing facility handoff to the wholesaler or pharmacy and continue to delivery to the end user. This may include thousands of miles or the last few feet until the product is administered. The “last mile” to the point of patient administration can prove difficult to manage. Health care professionals, patients and most retailers are, by and large, unaware of the challenges experienced during the “last mile.” Invariably, detailed and practical knowledge and information related to any product excursions beyond compendial ranges are unknown or unavailable to the end user.

This guidance document serves to complement the information provided in TR-39 by going beyond manufacturer-focused issues and addressing those issues specifically encountered within the “last mile.”

1.1 Purpose

The purpose of this document is to provide guidance to all involved in the “last mile” regarding the proper handling and storage of controlled-temperature medicinal products and devices.